Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158498 | 0.80 | — | — | |
| SCHEMBL9020969 | 0.80 | — | — | |
| SCHEMBL17433536 | 0.77 | BRD4 (0.68) | BRD4BRD2GAASMN1; SMN2 | |
| SCHEMBL24400455 | 0.75 | BRD4 (0.36) | BRD4BRD2 | |
| SCHEMBL2235528 | 0.75 | BRD4 (0.41) | BRD4BRD2GAASMN1; SMN2 | |
| SCHEMBL27030667 | 0.72 | PLA2G7 (0.36) | BRD4BRD2GSK3AGSK3B | |
| SCHEMBL22070 | 0.72 | — | — | |
| SCHEMBL17324575 | 0.72 | GAA (0.42) | BRD4BRD2GAA | |
| SCHEMBL13684324 | 0.72 | SMN1; SMN2 (0.41) | BRD4BRD2GAASMN1; SMN2 | |
| SCHEMBL6362000 | 0.72 | CHRM2 (0.33) | BRD4BRD2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016103280-A1 | STEROID-CHITOSAN KETIMINE NANOPARTICLES FOR ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-30 | — | — | WO | claimed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-3271353-A1 | 3-(4-ETHYNYLPHENYL)HEXAHYDROPYRIMIDIN-2,4-DIONE DERIVATIVES AS MODULATORS OF MGLUR4 | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-1317013-B1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEM CORP (JP) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016146600-A1 | 3-(4-ETHYNYLPHENYL)HEXAHYDROPYRIMIDIN-2,4-DIONE DERIVATIVES AS MODULATORS OF MGLUR4 | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-22 | — | — | WO | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-7727583-B2 | Method for the production of structured surfaces | BASF AKTIENGESELLSCHAFT (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727583-B2 | Method for the production of structured surfaces | BASF AKTIENGESELLSCHAFT (DE) | 2010-06-01 | — | — | US | disclosed |
| US-6942948-B2 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-09-13 | — | — | US | disclosed |
| US-20030165733-A1 | Nonaqueous electrolyte solution and secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1317013-A1 | NON-AQUEOUS ELECTROLYTE AND SECONDARY CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-5578633-A | VASOPRESSIN AND OXYTOCIN ANTAGONISTS | SANOFI (FR) | 1996-11-26 | — | — | US | disclosed |
| US-5481005-A | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5397801-A | Affinity for vasopressin and ocytocin receptors; disorders of nervous, cardiovascular and gastrointestinal systems | SANOFI (FR) | 1995-03-14 | — | — | US | disclosed |
| EP-0403366-B1 | Cyclomalto-oligosaccharide derivatives and processes for their preparation | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1995-02-22 | — | — | EP | disclosed |
| US-5338755-A | Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system | ELF SANOFI (FR) | 1994-08-16 | — | — | US | disclosed |
| EP-0403366-A2 | Cyclomalto-oligosaccharide derivatives and processes for their preparation | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1990-12-19 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | BRD4 3246/4885BRD2 3022/4885GAA 941/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | BRD4 1871/4885BRD2 3445/4885GAA 56/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | BRD4 2483/4885BRD2 1599/4885GAA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.